266 related articles for article (PubMed ID: 23680494)
1. A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications.
Nyren-Erickson EK; Jones JM; Srivastava DK; Mallik S
Biochim Biophys Acta; 2013 Oct; 1830(10):4445-55. PubMed ID: 23680494
[TBL] [Abstract][Full Text] [Related]
2. Catalytic properties of ADAM12 and its domain deletion mutants.
Jacobsen J; Visse R; Sørensen HP; Enghild JJ; Brew K; Wewer UM; Nagase H
Biochemistry; 2008 Jan; 47(2):537-47. PubMed ID: 18081311
[TBL] [Abstract][Full Text] [Related]
3. Role of ADAMs in cancer formation and progression.
Duffy MJ; McKiernan E; O'Donovan N; McGowan PM
Clin Cancer Res; 2009 Feb; 15(4):1140-4. PubMed ID: 19228719
[TBL] [Abstract][Full Text] [Related]
4. A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis.
Georges S; Chesneau J; Hervouet S; Taurelle J; Gouin F; Redini F; Padrines M; Heymann D; Fortun Y; Verrecchia F
Eur J Cancer; 2013 Jun; 49(9):2253-63. PubMed ID: 23490646
[TBL] [Abstract][Full Text] [Related]
5. ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer.
Duhachek-Muggy S; Zolkiewska A
BMC Cancer; 2015 Mar; 15():93. PubMed ID: 25886595
[TBL] [Abstract][Full Text] [Related]
6. A disintegrin and metalloproteinase 12 (ADAM12) localizes to invasive trophoblast, promotes cell invasion and directs column outgrowth in early placental development.
Aghababaei M; Perdu S; Irvine K; Beristain AG
Mol Hum Reprod; 2014 Mar; 20(3):235-49. PubMed ID: 24243624
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic diversity of breast cancer-related mutations in metalloproteinase-disintegrin ADAM12.
Qi Y; Duhachek-Muggy S; Li H; Zolkiewska A
PLoS One; 2014; 9(3):e92536. PubMed ID: 24651654
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).
Kveiborg M; Jacobsen J; Lee MH; Nagase H; Wewer UM; Murphy G
Biochem J; 2010 Aug; 430(1):79-86. PubMed ID: 20533908
[TBL] [Abstract][Full Text] [Related]
9. Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain.
Miller MA; Moss ML; Powell G; Petrovich R; Edwards L; Meyer AS; Griffith LG; Lauffenburger DA
Sci Rep; 2015 Oct; 5():15150. PubMed ID: 26477568
[TBL] [Abstract][Full Text] [Related]
10. ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins.
Fröhlich C; Klitgaard M; Noer JB; Kotzsch A; Nehammer C; Kronqvist P; Berthelsen J; Blobel C; Kveiborg M; Albrechtsen R; Wewer UM
Biochem J; 2013 May; 452(1):97-109. PubMed ID: 23458101
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
Stautz D; Wewer UM; Kveiborg M
PLoS One; 2012; 7(5):e37628. PubMed ID: 22662180
[TBL] [Abstract][Full Text] [Related]
12. Cellular roles of ADAM12 in health and disease.
Kveiborg M; Albrechtsen R; Couchman JR; Wewer UM
Int J Biochem Cell Biol; 2008; 40(9):1685-702. PubMed ID: 18342566
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis.
Taniguchi T; Asano Y; Akamata K; Aozasa N; Noda S; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jun; 27(6):747-53. PubMed ID: 22540429
[TBL] [Abstract][Full Text] [Related]
14. ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth.
Albrechtsen R; Kveiborg M; Stautz D; Vikeså J; Noer JB; Kotzsh A; Nielsen FC; Wewer UM; Fröhlich C
J Cell Sci; 2013 Oct; 126(Pt 20):4707-20. PubMed ID: 24006261
[TBL] [Abstract][Full Text] [Related]
15. Cell-surface metalloprotease ADAM12 is internalized by a clathrin- and Grb2-dependent mechanism.
Stautz D; Leyme A; Grandal MV; Albrechtsen R; van Deurs B; Wewer U; Kveiborg M
Traffic; 2012 Nov; 13(11):1532-46. PubMed ID: 22882974
[TBL] [Abstract][Full Text] [Related]
16. ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme.
Wewer UM; Mörgelin M; Holck P; Jacobsen J; Lydolph MC; Johnsen AH; Kveiborg M; Albrechtsen R
J Biol Chem; 2006 Apr; 281(14):9418-22. PubMed ID: 16455653
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic processing of delta-like 1 by ADAM proteases.
Dyczynska E; Sun D; Yi H; Sehara-Fujisawa A; Blobel CP; Zolkiewska A
J Biol Chem; 2007 Jan; 282(1):436-44. PubMed ID: 17107962
[TBL] [Abstract][Full Text] [Related]
18. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.
Asakura M; Kitakaze M; Takashima S; Liao Y; Ishikura F; Yoshinaka T; Ohmoto H; Node K; Yoshino K; Ishiguro H; Asanuma H; Sanada S; Matsumura Y; Takeda H; Beppu S; Tada M; Hori M; Higashiyama S
Nat Med; 2002 Jan; 8(1):35-40. PubMed ID: 11786904
[TBL] [Abstract][Full Text] [Related]
19. Quantitative proteomics identifies myoferlin as a novel regulator of A Disintegrin and Metalloproteinase 12 in HeLa cells.
Zhou Y; Xiong L; Zhang Y; Yu R; Jiang X; Xu G
J Proteomics; 2016 Oct; 148():94-104. PubMed ID: 27432471
[TBL] [Abstract][Full Text] [Related]
20. Effects of nitric oxide synthase deficiency on a disintegrin and metalloproteinase domain-containing protein 12 expression in mouse brain samples.
Lendeckel U; Wolke C; Bernstein HG; Keilhoff G
Mol Med Rep; 2015 Aug; 12(2):2253-62. PubMed ID: 25892053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
